Alexion Pharmaceuticals Inc

Most Recent

  • Alexion Acquisition AstraZeneca
    Healthcare

    AstraZeneca to Acquire Alexion for $39 Billion, Stock Down

    By Ambrish Shah
  • uploads///AdobeStock_
    Fund Managers

    Bridgewater: What Are Ray Dalio’s Top Investing Ideas?

    Founded by Ray Dalio, Bridgewater Associates’ top sell in the third quarter was the iShares MSCI Emerging Markets ETF (EEM).

    By Rabindra Samanta
  • uploads///amgens alexion acquisition
    Healthcare

    Amgen’s Alexion Acquisition: Does It Make Sense?

    On August 21, Spanish website Intereconomia reported that Amgen would be announcing its acquisition of Alexion Pharmaceuticals in the next few days.

    By Margaret Patrick
  • uploads///blood _
    Company & Industry Overviews

    Why Neurocrine Biosciences Stock Is Plummeting Today

    Today, Neurocrine Biosciences (NBIX) is trading at $67.91, a ~20.83% fall from its closing price of $85.76 on December 11.

    By Daniel Collins
  • uploads///Biomarin
    Company & Industry Overviews

    How BioMarin Pharmaceutical’s Financials Look in November

    BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.

    By Daniel Collins
  • uploads///ALXN
    Company & Industry Overviews

    How Analysts View Alexion Stock

    In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating.

    By Kenneth Smith
  • uploads///ALXN
    Company & Industry Overviews

    Analyzing Alexion Pharmaceuticals’ Product Performance

    Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma.

    By Kenneth Smith
  • uploads///syringe _
    Earnings Report

    Alexion Pharmaceuticals: What to Expect from Its Q3 Earnings

    Alexion Pharmaceuticals (ALXN) is scheduled to report its third-quarter earnings on October 24.

    By Kenneth Smith
  • uploads///SRPT
    Company & Industry Overviews

    A Look at Sarepta Therapeutics’ Stock Performance

    After its stellar rise from $54.02 on January 8 to a high of $161.51 on September 28, Sarepta stock has seen selling pressure amid the market volatility in October.

    By Kenneth Smith
  • uploads///SRPT
    Company & Industry Overviews

    Analyzing Sarepta’s Product Pipeline

    Sarepta is expected to incur R&D expenses of $277.8 million in fiscal 2018, compared with $166.71 million in fiscal 2017.

    By Kenneth Smith
  • uploads///capsule _
    Company & Industry Overviews

    How Alexion Pharmaceuticals Is Positioned in October

    In September, Alexion Pharmaceuticals agreed to acquire Syntimmune, a clinical stage biotechnology company.

    By Kenneth Smith
  • uploads///Portola
    Company & Industry Overviews

    A Look at Portola Pharmaceuticals’ Financial Performance

    Portola Pharmaceuticals’ (PTLA) net revenues grew from $3.79 million in the second quarter of 2017 to $4.01 million in the second quarter of 2018.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Revenue Growth Rate

    Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018.

    By Mike Benson
  • uploads///thermometer __
    Company & Industry Overviews

    Alexion Pharmaceuticals to Acquire Syntimmune

    In this series, we’ll look at how companies in the rare disease space have been performing, as well as recent news.

    By Daniel Collins
  • uploads///ALXN
    Company & Industry Overviews

    Alexion’s Soliris Continues to See Growth

    Alexion Pharmaceuticals’ (ALXN) products on the market include Soliris, Strensiq, and Kanuma.

    By Kenneth Smith
  • uploads///BMRN
    Company & Industry Overviews

    How BioMarin Pharmaceutical Is Positioned Financially in August

    In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017.

    By Daniel Collins
  • uploads///addiction _
    Company & Industry Overviews

    How Analysts View BioMarin Pharmaceutical in August

    On August 30, 2018, BioMarin Pharmaceutical (BMRN) stock closed at $99.26 which is 7% below its 52-week high of $106.20 on August 2.

    By Daniel Collins
  • uploads///ALNY
    Earnings Report

    What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?

    In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.

    By Kenneth Smith
  • uploads///Jazz analysts
    Earnings Report

    Wall Street Analysts Are Mostly Positive on Jazz Pharmaceuticals

    Jazz Pharmaceuticals anticipates net revenues to be in the range of $1.88 million to $1.93 million in fiscal 2018.

    By Daniel Collins
  • uploads///lab _
    Earnings Report

    How Did Jazz Pharmaceuticals Perform in the Second Quarter?

    Jazz Pharmaceuticals reported revenues of $500.5 million in Q2 2018 compared to $394.4 million in Q2 2017, a ~27% YoY increase and a ~13% sequential increase.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Analysts Are Bullish on Sarepta Therapeutics

    Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in Q1 2018.

    By Mike Benson
  • uploads///ALNY
    Earnings Report

    What Alnylam’s Bottom Line Is Expected to Look Like in Q2 2018

    Alnylam Pharmaceuticals’ (ALNY) selling, general, and administrative expenses are expected to rise 73.46%.

    By Kenneth Smith
  • uploads///addiction _
    Earnings Report

    How Does BioMarin Pharmaceutical Look ahead of Its Q2 Earnings?

    BioMarin Pharmaceutical (BMRN) plans to release its Q2 2018 results on August 2. In Q1 2018, BMRN reported net revenues of $373.4 million.

    By Daniel Collins
  • uploads///GILD
    Earnings Report

    What Gilead Sciences’ Bottom Line Is Expected to Look Like in Q2

    Gilead Sciences’ (GILD) research and development expenses are expected to increase 8.78%, from $812 million in Q2 2017 to $883.27 million in Q2 2018.

    By Kenneth Smith
  • uploads///ALXN
    Earnings Report

    Why Most Analysts Recommend a ‘Buy’ for Alexion Stock

    Analysts expect Alexion Pharmaceuticals’ (ALXN) interest expense to decline by 5.32% from $24 million in Q2 2017 to $22.72 million in Q2 2018.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    A Look at Incyte’s Valuation as of May 25

    Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.

    By Mike Benson
  • uploads///feature
    Company & Industry Overviews

    Vivus Stock Rose 60% Last Week

    Vivus stock rose 60% between May 11 and May 18.

    By Daniel Collins
  • uploads///ALXN
    Company & Industry Overviews

    Alexion Delivered a Solid Financial Performance in Q1 2018

    Alexion Pharmaceuticals (ALXN) generated total revenue of $931 million in the first quarter of 2018.

    By Kenneth Smith
  • uploads///ALXN research pipeline
    Company & Industry Overviews

    Exploring the Promising Research Pipeline of Alexion Therapeutics

    Alexion plans to begin a Phase 3 study of a subcutaneous formulation of ALXN1210 in late 2018.

    By Kenneth Smith
  • uploads///ALXN research pipeline
    Company & Industry Overviews

    Analyzing Alexion’s Acquisition of Wilson Therapeutics

    In April, Alexion announced a tender offer to acquire Sweden-based Wilson Therapeutics.

    By Kenneth Smith
  • uploads///stem cell _
    Company & Industry Overviews

    How Much Upside Do Analysts See in Alexion Stock?

    Of the 19 analysts covering Alexion Pharmaceuticals in May, 18 have given the stock “buy” or higher ratings.

    By Kenneth Smith
  • uploads///Analysts
    Earnings Report

    Recent Developments, Recommendations for JAZZ in May

    In May, Jazz Pharmaceuticals (JAZZ) submitted a supplemental new drug application to the FDA for the label expansion of Xyrem.

    By Daniel Collins
  • uploads///FeI
    Earnings Report

    How Did Jazz Pharmaceuticals Perform in 1Q18?

    In 1Q18, Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million compared to $376.1 million in 1Q17.

    By Daniel Collins
  • uploads///recommendations
    Company & Industry Overviews

    Alexion: Analysts Raise Their Target Prices

    As of April 12, 2018, 18 analysts gave a “buy” or “strong buy” recommendation on Alexion stock, while one analyst gave a “hold” recommendation.

    By Sarah Collins
  • uploads///CURRENT TREATMENT LIMITATIONS
    Healthcare

    WTX101: A Superior Treatment for Wilson Disease

    WTX101 has a unique action mechanism. The drug has the potential to become the standard of care for Wilson disease patients.

    By Sarah Collins
  • uploads///WILSON DISEASE
    Healthcare

    Wilson Disease: A Market Opportunity for Alexion

    Wilson Therapeutics is developing a drug to treat Wilson disease. Wilson disease is a rare genetic disorder that’s potentially life-threatening.

    By Sarah Collins
  • uploads///STRATEGIC RATIONALE
    Company & Industry Overviews

    Strategic Rationale behind Alexion’s Acquisition

    Acquiring Wilson Therapeutics is expected to be a strategic fit for Alexion. Alexion is focused on developing life-transforming rare disease therapies.

    By Sarah Collins
  • uploads///business _
    Healthcare

    Alexion to Acquire Wilson Therapeutics for $855 Million

    On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders.

    By Sarah Collins
  • uploads///Strensiq
    Company & Industry Overviews

    Alexion Pharmaceuticals: Strensiq and Kanuma in 2017

    In 4Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenues of $95.6 million, which reflected ~35% growth on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///FD
    Company & Industry Overviews

    Alexion Pharmaceuticals in 4Q17 and Fiscal 2017

    In 4Q17, Alexion Pharmaceuticals (ALXN) generated revenues of $910 million, which reflected ~10% growth on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///rare diseases
    Company & Industry Overviews

    Inside Pfizer’s Rare Disease Segment Performance in 2017

    In 4Q17, Pfizer’s BeneFix reported revenues of $150 million, which represents a ~11% decline YoY and a ~1% decline quarter-over-quarter.

    By Daniel Collins
  • uploads///Spinraza
    Company & Industry Overviews

    How Biogen’s Spinraza Is Positioned for 2018

    In 4Q17, Biogen’s (BIIB) Spinraza generated revenues of $363 million, which reflected 34% quarter-over-quarter growth.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    A Look at Ionis Pharmaceuticals’ January 2018 Valuation

    On January 5, Ionis Pharmaceuticals’ stock value had risen ~4.3% over the last 12 months. Analysts expect the stock to rise ~14.0% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How’s Incyte’s Valuation in January 2018?

    Analysts expect Incyte Corporation’s revenue to rise ~26.7% to $413.8 million in 4Q17 compared to $326.5 million in 4Q16.

    By Mike Benson
  • uploads///digital science capabilities
    Company & Industry Overviews

    Thermo Fisher Scientific’s Deepening Ties with Sema4

    Thermo Fisher Scientific’s (TMO) Core Informatics’ Platform for Science’s modules, including a LIMS (laboratory information management system), could soon be implemented at Sema4’s two major laboratory facilities.

    By Sarah Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Analyst Recommendations for Alexion in December 2017

    Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Confirmatory Studies May Expand Uptake of Exondys 51

    Demand trends Sarepta Therapeutics (SRPT) reported that by the end of 3Q17, all Tier 1 and Tier 2 sites, which will be treating around 75% of DMD (Duchenne muscular dystrophy) patients with mutations amenable to exon-51 skipping, had submitted start forms for Exondys 51 (eteplirsen). The company has also witnessed an increase in start forms submitted […]

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Givosiran May Become Major Growth Driver for Alnylam Pharmaceuticals

    On September 7, 2017, Alnylam Pharmaceuticals (ALNY) announced that it had reached an agreement with the US Food and Drug Administration (or FDA) related to the design of the phase three program for investigational RNAi therapeutic Givosiran.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Patisiran Expected to Become Key Growth Driver for Alnylam

    Alnylam Pharmaceuticals’ (ALNY) investigational drug Patisiran is expected to target 20,000 to 30,000 patients with hereditary ATTR (or hATTR) Amyloidosis with polyneuropathy caused by amyloid deposition in nerves.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Spinraza Continues to See Improvement in Sales Metrics in 2017

    Biogen (BIIB) and Ionis Pharmaceuticals’ (IONS) Spinraza has been witnessing improvement in infrastructure and payer access for spinal muscular atrophy (or SMA) patients in the US in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Spinraza Has Emerged as Key Growth Driver for Ionis in 2017

    In 1H17, Ionis Pharmaceuticals (IONS) recorded revenues of about $27.6 million related to royalty income received from Biogen from Spinraza sales.

    By Margaret Patrick
  • uploads///Analysts Rating
    Earnings Report

    Analysts’ Recommendations for Biogen in October 2017

    Recent developments In October 2017, Biogen (BIIB) and Eisai expanded their existing agreement on the joint development and commercialization of Alzheimer’s disease therapies under investigation. According to the terms of the agreement, Eisai has the option to co-develop and co-commercialize Biogen’s aducanumab for the treatment of Alzheimer’s disease patients. The present expansion of the agreement […]

    By Daniel Collins
  • uploads///Soliris
    Company & Industry Overviews

    Gauging Alexion’s 2018 Growth with Soliris

    In 2Q17, Alexion Pharmaceuticals’ (ALXN) Soliris generated revenues of ~$814 million, which represented a ~16% YoY rise and a ~4% QoQ rise.

    By Daniel Collins
  • uploads///BioMarin product
    Company & Industry Overviews

    How Did BioMarin Pharmaceuticals’ Drugs Perform in 1H17?

    In 2Q17, BioMarin Pharmaceuticals’ (BMRN) Aldurazyme generated revenues of around $20 million, which was a ~6% increase on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Defitelio
    Company & Industry Overviews

    How Is Jazz’s Defitelio Positioned after 2Q17?

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of ~$30 million, which represents a ~10% fall YoY and a ~17% fall QoQ.

    By Daniel Collins
  • uploads///Clinical trial
    Company & Industry Overviews

    This Part of Bioverativ’s Pipeline Could Be a Major Long-Term Growth Driver

    In June 2017, the FDA accepted Bioverativ’s investigative new drug application for BIVV001, a drug designed to treat prophylaxis from bleeding associated with hemophilia A.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Behind Bioverativ’s Analyst Recommendations This September

    Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”

    By Daniel Collins
  • uploads///Orkambi Kalydeco
    Company & Industry Overviews

    How Are Orkambi and Kalydeco Positioned after 2Q17?

    In 2Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $324 million, which reflected a whopping ~32% growth on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Rare disease
    Company & Industry Overviews

    How Pfizer’s Rare Disease Franchise Stands after 2Q17

    In 1H17, BeneFix generated revenues of ~$302 million, which reflected an ~18% decline on a YoY basis.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Analysts’ Recommendations for Pfizer in August 2017

    Of the 22 analysts covering Pfizer (PFE) in August 2017, one analyst recommended a “strong buy” and ten analysts recommended a “buy.” On August 26, Pfizer had a consensus 12-month target price of $37.45 for a 12.7% return on investment.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    New Patients and Alexion Pharmaceuticals’ Metabolic Franchise

    Alexion Pharmaceuticals (ALXN) has reiterated its 2017 revenue guidance of $375.0 million–$400.0 million for its metabolic franchise.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alexion Pharmaceuticals Expects Robust Revenue for Soliris

    Alexion Pharmaceuticals (ALXN) raised its 2017 revenue projections for Soliris from $3.025 billion–$3.1 billion to $3.075 billion–$3.125 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alexion Pharmaceuticals Raised 2017 Earnings Guidance

    Alexion Pharmaceuticals (ALXN) raised its 2017 non-GAAP guidance from the previously estimated $5.10–$5.30 to $5.40–$5.55.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alprolix and Eloctate Increasingly Used for Prophylaxis in 2017

    Since demand from the target population for prophylaxis is rising rapidly, Bioverativ’s Alprolix and Eloctate are expected to see solid demand trends in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ Expected to Report Healthy Profit Margins in 2017

    Bioverativ (BIVV) expects its 2017 GAAP and non-GAAP operating margins to fall 38.0%–42.0% and 43.0%–47.0%, respectively.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ Expected to Report Robust Revenue Growth in 2017

    In 1Q17, Bioverativ reported revenues close to $259.0 million, driven by its focus on a commercial strategy for its hemophilia products and optimal cost management.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ–True North Therapeutics: Stronger Research Pipeline

    The acquisition of True North Therapeutics has paved the way for Bioverativ’s (BIVV) entry into cold agglutinin disease (or CAD).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vertex Pharmaceuticals Cystic Fibrosis Market Could Expand

    Vertex Pharmaceuticals’ (VRTX) drugs, Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), are capable of treating around 30,000 cystic fibrosis (or CF) patients.

    By Margaret Patrick
  • uploads///Analysts Recommendations
    Company & Industry Overviews

    What Analysts Recommend for BioMarin Pharmaceuticals

    A total of 20 analysts were analyzing BioMarin Pharmaceuticals in July 2017. Six analysts recommended a “strong buy,” while nine analysts suggested a “buy.”

    By Daniel Collins
  • uploads///Naglazyme Aldurazyme revenues
    Company & Industry Overviews

    BioMarin Expects These Drugs to Generate Steady Revenues

    In 2016, BioMarin Pharmaceuticals’ (BMRN) Naglazyme generated revenues of around $297 million, a ~2% year-over-year (or YoY) decline.

    By Daniel Collins
  • uploads///BioMarin performance projections
    Company & Industry Overviews

    What to Expect from BioMarin Pharmaceuticals in 2017

    In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    How Incyte’s Valuation Has Changed since 1Q17 Results

    Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.

    By Mike Benson
  • uploads///Analysts Rating
    Company & Industry Overviews

    Analysts’ Views on Alexion Pharmaceuticals and Its Peers

    Of the 21 analysts analyzing Alexion Pharmaceuticals, six analysts recommended a “strong buy” and 11 analysts recommended a “buy.”

    By Daniel Collins
  • uploads///Strensiq Revenues
    Company & Industry Overviews

    Strensiq: Key Growth Driver for Alexion Pharmaceuticals in 2017

    In 1Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenue of ~$74 million, which reflects ~4% quarter-over-quarter and ~124% YoY growth.

    By Daniel Collins
  • uploads///Soliris Revenue
    Company & Industry Overviews

    Soliris Is Expected to Continue Generating High Revenue

    In 1Q17, Alexion Pharmaceuticals’ (ALXN) Soliris generated revenue of ~$783 million, which is ~18% YoY (year-over-year) growth.

    By Daniel Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    Healthcare Sector Overview: Week of May 22–26, 2017

    Through May 26, 2017, 83% of healthcare stocks have delivered earnings above analysts’ estimates. About 16% of healthcare stocks have missed analysts’ estimates, while 2% reported earnings in line with analysts’ estimates.

    By Alexis Tate
  • uploads///Graph
    Company & Industry Overviews

    ALXN1210 Is Expected to Boost Alexion Pharmaceuticals’ Revenue

    Alexion Pharmaceuticals has planned five clinical trials in 2017 to test the potential of investigational next-generation C5 antibody, ALXN1210, as a treatment option for complement-mediated diseases.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alexion Pharmaceuticals Projects Robust 2017 Revenue Performance

    Alexion Pharmaceuticals (ALXN) expects to report revenue in the range of $3.4 billion–$3.5 billion in 2017.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Biogen’s Targeted Marketing Strategy for Spinraza in 1Q17

    To promote the use of Spinraza for SMA, Biogen (BIIB) has been actively educating and creating awareness for the drug among physician and patient communities.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Biogen Has Developed a Robust Access Strategy for Spinraza

    In 1Q17, Biogen’s (BIIB) Spinraza earned revenues of $47.0 million, of which $46.0 million were from the US market.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Biogen’s Spinraza Witnessed Robust Patient Demand in 1Q17

    Spinraza, Biogen’s (BIIB) SMA (spinal muscular atrophy) therapy, was approved by the FDA (U.S. Food and Drug Administration) on December 23, 2016.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Valeant’s Net Profit Margins Expected to Narrow in 2017

    Net profit margins Valeant Pharmaceuticals (VRX) has projected its adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) to fall $3.6 billion–$3.7 billion. Besides lower revenue, the company will also have to bear $1.9 billion in cash interest in 2017, which includes $100 million in amortized deferred financing costs. Wall Street analysts have projected that […]

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Valeant Pharmaceuticals Expects Lower Revenue in 2017

    Decline in revenue In fiscal 2017, Valeant Pharmaceuticals (VRX) expects to report revenue of $8.9 billion–$9.1 billion. This projection is based on foreign exchange rates in February 2017. It also includes revenue expected from sales of the company’s skincare products, as Valeant does not expect the divestiture transactions to be completed before the end of 2017. Wall […]

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis

    The European Medicines Agency (or EMA) has approved tafamidis for stage 1 hATTR amyloidosis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Do Analysts View Alnylam Pharmaceuticals in 2017?

    Of the 15 analysts covering Alnylam Pharmaceuticals (ALNY) in February 2017, two rated the company as a “strong buy,” six rated it as a “buy,” and seven rated ALNY as a “hold.”

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Alexion Expects from Its Metabolic Disease Drugs in 2017

    For fiscal 2017, Alexion (ALXN) has projected its metabolic disease franchise to earn revenues in the range of $375 million–$400 million.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alexion’s Soliris: Gauging Patient Demand

    For fiscal 2017, Alexion Pharmaceuticals (ALXN) expects to Soliris’ sales to be in the range of $3.02 billion–$3.10 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Alexion’s Latest Analyst Recommendations

    In 2016, Alexion (ALXN) reported revenues of nearly $3.1 billion, which represents a YoY growth of ~18%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vertex Expects Modest Revenue Growth in This

    Vertex (VRTX) has projected Orkambi’s revenues to fall in the range of $1.0 billion–$1.3 billion in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Strensiq Boosted Alexion Pharmaceuticals’ Revenues in 2016

    On October 23, 2015, Alexion Pharmaceuticals’ Strensiq was approved by the FDA as therapy for perinatal, infantile and juvenile-onset HPP patients.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Will Soliris Drive Alexion Pharmaceuticals’ Revenues in 2017?

    In 2016, Alexion Pharmaceuticals (ALXN) continued to witness solid uptake for Soliris. It witnessed strong demand in the AHUS segment around the world.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vertex Has Adopted Multiple Approaches to Treat Cystic Fibrosis

    Vertex Pharmaceuticals (VRTX) is aiming to increase the number of patients eligible to be treated with its drugs to include the entire CF patient population.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why United Therapeutics Expects Strong Revenue Growth

    United Therapeutics (UTHR) expects to earn revenue exceeding $1.5 billion in 2016. By 2020, the company also expects to surpass its goal of $2 billion in annual revenue.

    By Margaret Patrick
  • uploads///anr
    Company & Industry Overviews

    What Are Analysts Saying about Horizon Pharma?

    According to a Thomson Reuters Eikon consensus of six brokerage firms on December 17, 2016, 83.3% of the firms rated Horizon Pharma (HZNP) a “buy.”

    By Jillian Dabney
  • uploads///krystexxa
    Company & Industry Overviews

    Revenue Drivers for Krystexxa, Horizon’s Orphan Biologic Drug

    Horizon plans to drive Krystexxa through increased awareness and outreach, investing in its marketing and medical education as well as commercial infrastructure.

    By Jillian Dabney
  • uploads///segments
    Company & Industry Overviews

    How Did Horizon Pharma Perform in 3Q16?

    In 3Q16, Horizon Pharma’s (HZNP) net sales on a GAAP basis fell to $208.7 million. Non-GAAP net sales were $273.7 million.

    By Jillian Dabney
  • uploads///Actimmune trials
    Company & Industry Overviews

    Horizon Pharma’s Steep Fall in December: What Happened?

    On December 8, 2016, Horizon Pharma (HZNP) announced that its Phase 3 STEADFAST trial for Actimmune didn’t meet its primary endpoint. Horizon stock fell 22.5% that day.

    By Jillian Dabney
  • uploads///acq flexibility
    Company & Industry Overviews

    How Could Gilead Sciences Restore Its Growth?

    With its continuous revenue fall, Gilead Sciences (GILD) could opt to restore its growth through acquisitions.

    By Jillian Dabney
  • uploads///ANR
    Earnings Report

    What Do Analysts Say about Regeneron after 3Q16 Earnings?

    Regeneron Pharmaceuticals (REGN) released earnings for 3Q16 on November 4, 2016.

    By Jillian Dabney
  • uploads///revue ee
    Earnings Report

    BioMarin’s Disappointing 3Q16 Earnings

    BioMarin Pharmaceutical (BMRN) reported its 3Q16 earnings on October 27, 2016. Revenues were $279.9 million, which was lower than Wall Street analysts’ projections.

    By Jillian Dabney
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.